Rubicon Research Share Price Target: Shares of pharmaceutical company Rubicon Research are in focus following news of its acquisition of a majority stake in Arinna Lifesciences. Despite the development, domestic brokerage firm Motilal Oswal has reiterated a BUY recommendation on the stock and raised its price target by nearly 6 per cent.
The acquisition is structured as a cash transaction. Arinna has been valued at an enterprise value of Rs 200 crore on a cash- and debt-free basis, with the final consideration subject to closing adjustments.
About Arinna Lifesciences
Founded in 2013, Arinna Lifesciences operates in the Indian domestic market with a portfolio that includes antiepileptics, antidepressants, and antipsychotics.
The company reported a turnover of Rs 71.5 crore for the financial year ending March 2025, up from Rs 65.14 crore in FY24 and Rs 60.06 crore in FY23.
Brokerage View and Revised Price Target
Motilal Oswal has maintained its BUY call on the stock and increased the price target to Rs 955 from the earlier Rs 905. The current price target reflects an upside of 15 per cent from the current market price.
The brokerage highlighted Rubicon’s strategic move to expand into the central nervous system (CNS) therapy segment in India’s branded pharmaceutical market through its association with Arinna Lifesciences. This is expected to strengthen the company’s domestic presence.
A key advantage of this strategy is access to Arinna’s well-established distribution network, including stockists, retail pharmacies, and a strong base of prescribing physicians.
Additionally, the acquisition is seen as a logical step that will enable Rubicon to leverage its US pipeline and introduce innovative products to the Indian market.
Factoring in the potential earnings upside from these initiatives, Motilal Oswal has also increased the company’s valuation multiple, raising the P/E ratio to 37x from 35x.
Rubicon Research Share Price
As of 10:00 am, Rubicon Research’s stock price was up 1.2 per cent (Rs 9.55) at Rs 830.20. The stock touched an intraday high of Rs 869, reflecting an upside of 5.8 per cent from the previous close of Rs 821.30.
Rubicon Research Performance
Rubicon Research’s stock performance shows mixed trends across different timeframes. The stock is down 2.45 per cent over the past week. However, it has gained 11.72 per cent over the past month and is up 23.46 per cent year-to-date.
Disclaimer: This article is automated and reviewed by users. It is intended for informational purposes only and should not be taken as investment advice. Please consult your financial advisor before making any investment decisions.
